Antacids Containing Calcium

Concomitant use may decrease neratinib AUC, reducing NERLYNX activity. Separate administration by at least 3 hours after antacid dose.

Avoid concomitant use. If unavoidable, modify KOMZIFTI administration time to separate dosing.

Antacids may interact with iron (ferrous fumarate), potentially affecting iron absorption and efficacy.

Antacid may decrease acalabrutinib plasma concentrations. Separate dosing by at least 2 hours.

Antacids interfere with absorption of alendronate sodium. Patients should wait at least one-half hour after taking alendronate sodium before taking antacids.

Antacids interfere with absorption of alendronate. Patients should wait at least 30 minutes after taking the medication before taking antacids.

Reduce atazanavir plasma concentrations by increasing gastric pH, potentially reducing REYATAZ's therapeutic effect.

Decreased absorption of the triple therapy capsules; do not take concomitantly.

Decrease cabotegravir concentration; administer antacid products separately.

Short-acting antacids may reduce gastric acidity and lower bioavailability of cefuroxime axetil. Administer cefuroxime axetil at least 1 hour before or 2 hours after antacids.

Antacids can reduce absorption of chloroquine; an interval of at least 4 hours between intake should be observed.

Avoid simultaneous administration. Administer at least 2 hours before or after dasatinib dose to prevent decreased concentrations.

Coadministration of antacids could alter the release of dexmethylphenidate due to pH-dependent modified release characteristics.

Antacids may interfere with the absorption of dicyclomine hydrochloride; simultaneous use should be avoided.

Concomitant administration may reduce plasma levels of diflunisal, with clinically significant effects when antacids are used on a continuous schedule.

Decrease digoxin concentrations. Requires monitoring and dose adjustment.

Antacids containing calcium impair the absorption of tetracyclines.

Antacids containing calcium impair absorption of tetracyclines.

Antacids impair gastrointestinal folate uptake through pH elevation.

Elevates gastric pH and may reduce gefitinib plasma concentrations. Separate gefitinib dosing by 6 hours before or after administration.

Antacids can reduce absorption of chloroquine; an interval of at least 4 hours between intake is recommended.

Absorption of antacids may be decreased during concurrent use due to decreased gastrointestinal motility and delayed gastric emptying.

Antacids interfere with absorption of ibandronate. Patients should take ibandronate at least 60 minutes before antacids.

Nonabsorbable antacids may inhibit the lactulose-induced drop in colonic pH, potentially reducing treatment efficacy. Monitor for lack of desired effect.

Nonabsorbable antacids given concurrently may inhibit the desired lactulose-induced drop in colonic pH, potentially reducing treatment efficacy.

Magnesium or aluminum-containing antacids decrease levofloxacin absorption if taken within 2 hours. Separate dosing by at least 2 hours.

May form an insoluble chelate with levothyroxine, binding and delaying or preventing absorption, potentially resulting in hypothyroidism.

Antacids may interfere with dissolution of mesalamine extended-release capsule coating due to pH effects; avoid co-administration.

May reduce absorption of hyoscyamine and cause urine to become alkaline, reducing methenamine effectiveness. Doses should be spaced 1 hour apart.

May reduce absorption of hyoscyamine and cause urine alkalinity, reducing methenamine effectiveness. Doses should be spaced 1 hour apart.

Concomitant administration with antacids may interfere with the absorption of methscopolamine bromide.

Antacids containing calcium impair absorption of tetracyclines.

Antacids containing calcium impair absorption of tetracyclines.

Multivalent cations in antacids form chelates with moxifloxacin, substantially decreasing absorption. Take moxifloxacin at least 4 hours before or 8 hours after antacids.

Multivalent cations in antacids form chelates with moxifloxacin, substantially decreasing absorption. Take moxifloxacin at least 4 hours before or 8 hours after antacids.

Multivalent cations in antacids form chelates with moxifloxacin, substantially decreasing absorption. Take moxifloxacin at least 4 hours before or 8 hours after antacids.

Antacids may interact with iron, potentially affecting iron absorption and efficacy.

Absorption of omadacycline is impaired by antacids containing calcium.

May decrease phenytoin serum levels by affecting absorption; should not be taken at same time.

May decrease phenytoin serum levels by affecting absorption; should not be taken at the same time of day.

Do not take bisacodyl delayed-release tablet within one hour of taking an antacid to avoid reduced effectiveness.

Calcium-containing antacids may bind phosphate and prevent its absorption.

Decreases raltegravir plasma concentrations. Coadministration not recommended despite no dose adjustment needed for ISENTRESS.

Concomitant intake may cause significant decreases in rilpivirine plasma concentrations. Administer at least 2 hours before or 4 hours after rilpivirine.

Coadministration may cause significant decreases in rilpivirine plasma concentrations due to increase in gastric pH. Antacids should be administered at least 2 hours before or 4 hours after rilpivirine.

Antacids decrease rilzabrutinib exposure due to pH-dependent solubility. Administer WAYRILZ at least 2 hours before antacids.

Antacids interfere with the absorption of risedronate when co-administered.

Antacids containing calcium impair absorption of tetracyclines.

May reduce absorption of hyoscyamine and cause urine to become alkaline, reducing methenamine effectiveness. Space doses 1 hour apart.

Antacid administration 5 minutes before cefprozil capsules did not affect bioavailability.

Reduce diazepam peak concentrations by 30% and slow rate of absorption with 20-25 minute delay in peak achievement, but no effect on extent of absorption.

Antacids can decrease peak concentration of etodolac by 15-20% but have no effect on time-to-peak or extent of absorption.

Bioavailability of olmesartan was not significantly altered by co-administration of aluminum hydroxide/magnesium hydroxide.

Co-administration of Maalox did not affect ziprasidone pharmacokinetics.